68Ga-PSMA PET/CT could aid in detecting a recurrence in RAI-R patients, identifying metastases in TENIS patients, and selecting patients who could benefit from PSMA-targeted radionuclide therapy (177Lu-PSMA-617), particularly those with metastatic dedifferentiated thyroid cancer. Here, FOLH1 is linked to thyroid gland carcinoma.